Patient Case 4: A 38-Year-Old Woman With Functional High-Risk MM With Progressive Disease at Day 60 Post ASCT—Next Treatment Approaches

One concern with bispecific antibody therapies in community settings is managing adverse events, with emerging patterns guiding management strategies.

In this episode of Targeted Talks, Binod Dhakal, MD, MS, discusses the recent FDA approval of ciltacabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma.

The FDA has accepted the resubmitted biologics license application for linvoseltamab to treat relapsed/refractory multiple myeloma in heavily pretreated adults.

In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.

During a Case-Based Roundtable® event, Rahul Banerjee, MD, discussed approaches to dosing and tolerability when using talquetamab in patients with relapsed/refractory multiple myeloma.

The phase 3 IRAKLIA trial of subcutaneous isatuximab met its co-primary end points in multiple myeloma.